



Attorney's Docket No. 45922/241203 (5865-2)

PATENT

PH#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Gambacorti-Passerini, et al. Confirmation No.: 4010
Appl. No.: 10/008,377 Group Art Unit: 1642
Filed: November 15, 2001 Examiner: To be assigned
For: IMMUNOGENIC ALK PEPTIDES

July 30, 2002

Commissioner for Patents
Washington, DC 20231

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Patricia L. Chisholm
Patricia L. Chisholm
Registration No. 45,822

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

"Express Mail" Mailing Label Number EL 868644266 US
Date of Deposit: July 30, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner For Patents, Washington, DC 20231.

Pamela Lockley
Pamela Lockley

Substitute for form 1449A/PTO
(Revised 10/2001)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/008,377
Filing Date November 15, 2001
First Named Inventor Gambacorti-Passerini
Group Art Unit 1642
Examiner Name To be assigned
Attorney Docket Number 45922/241203 (5865-2)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-5,529,925	06-25-1996	Morris <i>et al.</i>	
	2	US-5,770,421	06-23-1998	Morris <i>et al.</i>	
	3	US-6,174,674 B1	01-16-2001	Morris <i>et al.</i>	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO
(Revised 10/2001)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/008,377
Filing Date	November 15, 2001
First Named Inventor	Gambacorti-Passerini
Group Art Unit	1642
Examiner Name	To be assigned
Attorney Docket Number	45922/241203 (5865-2)

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	4	DREXLER, H., <i>et al.</i> , "Pathobiology of NPM-ALK and Variant Fusion Genes in Anaplastic Large Cell Lymphoma and Other Lymphomas," <i>Leukemia</i> , 2000, pp. 1533-1559, Vol. 14, Macmillan Publishers Ltd.	
	5	MORRIS, S., <i>et al.</i> , "Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma," <i>Science</i> , March 1994, pp. 1281-1284, Vol. 263 (5151), American Association for the Advancement of Science, USA.	
	6	MORRIS, S., <i>et al.</i> , "Sequence Correction," <i>Science</i> , January 1995, pp. 316-317, Vol. 267(5196), American Association for the Advancement of Science, USA.	
	7	PASSONI, L., <i>et al.</i> , "ALK as a Novel Lymphoma-Associated Tumor Antigen: Identification of 2 HLA-A2.1-Restricted CD8 ⁺ T-cell Epitopes," <i>Blood</i> , March 2002, pp. 2100-2106, Vol. 99(6), The American Society of Hematology, USA.	
	8	PULFORD, K., <i>et al.</i> , "Immune Response to the ALK Oncogenic Tyrosine Kinase in Patients with Anaplastic Large-Cell Lymphoma," <i>Blood</i> , August 2000, pp. 1605-1607, Vol. 96(4), The American Society of Hematology, USA.	
	9	PASSONI, L., <i>et al.</i> , "In Vitro Induction of Primary HLA Class I-Restricted Immune Response Against ALK Kinase," Experimental Lymphoma Therapy, Poster Board No. 509, Session II, Abstract #1459.	

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.